日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Correction: The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer

更正:新型c-Met抑制剂卡博替尼可克服胰腺癌中的吉西他滨耐药性和干细胞信号传导。

Hage, C; Rausch, V; Giese, N; Giese, T; Schönsiegel, F; Labsch, S; Nwaeburu, C; Mattern, J; Gladkich, J; Herr, I

Triptolide reverses hypoxia-induced epithelial-mesenchymal transition and stem-like features in pancreatic cancer by NF-κB downregulation

雷公藤内酯醇通过下调 NF-κB 逆转胰腺癌缺氧诱导的上皮间质转化和干细胞样特征

Li Liu, Alexei V Salnikov, Nathalie Bauer, Ewa Aleksandrowicz, Sabrina Labsch, Clifford Nwaeburu, Jürgen Mattern, Jury Gladkich, Peter Schemmer, Jens Werner, Ingrid Herr

Sulforaphane and TRAIL induce a synergistic elimination of advanced prostate cancer stem-like cells

萝卜硫素和 TRAIL 协同诱导晚期前列腺癌干细胞样细胞消除

Sabrina Labsch, Li Liu, Nathalie Bauer, Yiyao Zhang, Ewa Aleksandrowicz, Jury Gladkich, Frank Schönsiegel, Ingrid Herr

Sulforaphane counteracts aggressiveness of pancreatic cancer driven by dysregulated Cx43-mediated gap junctional intercellular communication

萝卜硫素可抵消由 Cx43 介导的间隙连接细胞间通讯失调引起的胰腺癌的侵袭性

Tobias Forster, Vanessa Rausch, Yiyao Zhang, Orkhan Isayev, Katharina Heilmann, Frank Schoensiegel, Li Liu, Michelle Nessling, Karsten Richter, Sabrina Labsch, Clifford C Nwaeburu, Juergen Mattern, Jury Gladkich, Nathalia Giese, Jens Werner, Peter Schemmer, Wolfgang Gross, Martha M Gebhard, Clarissa

The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer

新型 c-Met 抑制剂卡博替尼可克服胰腺癌中的吉西他滨耐药性和干细胞信号传导

C Hage, V Rausch, N Giese, T Giese, F Schönsiegel, S Labsch, C Nwaeburu, J Mattern, J Gladkich, I Herr

Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate

萝卜硫素可增强药物介导的胰腺和前列腺癌干细胞样细胞的细胞毒性

Georgios Kallifatidis, Sabrina Labsch, Vanessa Rausch, Juergen Mattern, Jury Gladkich, Gerhard Moldenhauer, Markus W Büchler, Alexei V Salnikov, Ingrid Herr